Table 2.
Baseline Characteristics of Study Patients Based on Response
| Variables | Response Group (n=30) | Non-Response Group (n=10) | P |
|---|---|---|---|
| Sex | 0.63 | ||
| Male | 26 | 8 | |
| Female | 4 | 2 | |
| Age (Y) | 58.4±8.88(41~82) | 48.6±4.43(28~67) | 0.06 |
| Etiology | 0.77 | ||
| Virus related | 21 | 8 | |
| Hepatitis B | 20 | 8 | |
| Hepatitis C | 1 | 0 | |
| Alcohol | 3 | 1 | |
| Primary cholestatic hepatitis | 1 | 0 | |
| others | 5 | 1 | |
| AFP (ug/L) | 0.23 | ||
| ≥400 | 7 | 5 | |
| <400 | 23 | 5 | |
| Child-Pugh class | 0.48 | ||
| No cirrhosis | 1 | 0 | |
| A | 24 | 10 | |
| B | 5 | 0 | |
| BCLC staging | 0.47 | ||
| A | 16 | 4 | |
| B | 0 | 0 | |
| C | 14 | 6 | |
| ECOG performance status | 0.23 | ||
| 0 | 19 | 9 | |
| 1 | 11 | 1 | |
| ADC values (×10−3mm2/s) | 1.51±0.32 (1.05~2.20) | 1.09±0.17 (0.87~1.31) | <0.001 |
| PVTT | 5/30 | 7/10 | 0.005 |
| Size of tumor (cm) | 9.42±3.18 (5.05~16.06) | 9.89±3.30 (5.04~14.72) | 0.69 |
| N of procedures | |||
| TACE+RFA | 2.33±1.37 (1~5) | 1.90±0.74 (1~3) | 0.22 |
| TACE | 1.53±0.86 (1~3) | 1.50±1.08 (1~4) | 0.92 |
| Anticancer agent | |||
| Fluorouracil | 22/30 | 9/10 | 0.51 |
| Adriamycin | 22/30 | 8/10 | 0.52 |
| Epirubicin | 8/30 | 2/10 | 0.52 |
| Cisplatin | 24/30 | 5/10 | 0.15 |
Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ADC, apparent diffusion coefficient; PVTT, portal vein thrombosis; ECOG, Eastern Cooperative Oncology Group.